Rudy Li
Stock Analyst at Wolfe Research
(4.91)
# 233
Out of 4,988 analysts
80
Total ratings
59.4%
Success rate
72.6%
Average return
Main Sectors:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings | Initiated Coverage: Buy | $60 | $42.02 | +42.79% | 1 | Aug 26, 2026 | |
| IMUX Immunic | Reiterated: Buy | $30 → $25 | $10.62 | +135.40% | 3 | Aug 11, 2026 | |
| STOK Stoke Therapeutics | Reiterated: Buy | $40 | $28.43 | +40.70% | 20 | Aug 3, 2026 | |
| QURE uniQure | Upgraded: Buy | $65 | $44.00 | +47.73% | 2 | Jul 29, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $18 | $15.19 | +18.50% | 1 | Jul 7, 2026 | |
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $45 | $42.47 | +5.96% | 1 | Jul 7, 2026 | |
| SPTX Seaport Therapeutics | Initiated Coverage: Hold | n/a | $21.39 | - | 1 | Jul 7, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $33 | $27.29 | +20.92% | 2 | May 6, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $160 | $146.23 | +9.42% | 2 | Apr 6, 2026 | |
| PRAX Praxis Precision Medicines | Reiterated: Buy | $500 | $298.95 | +67.25% | 7 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $45 | $43.39 | +3.71% | 2 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $230 | $207.78 | +10.69% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 → $25 | $38.81 | -35.58% | 11 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $19.72 | - | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 → $60 | $39.75 | +50.94% | 5 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $8.58 | +109.79% | 15 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $30.27 | -50.45% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $0.48 | +8,233.33% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 | $60.98 | n/a | 2 | May 21, 2025 |
Harmony Biosciences Holdings
Aug 26, 2026
Initiated Coverage: Buy
Price Target: $60
Current: $42.02
Upside: +42.79%
Immunic
Aug 11, 2026
Reiterated: Buy
Price Target: $30 → $25
Current: $10.62
Upside: +135.40%
Stoke Therapeutics
Aug 3, 2026
Reiterated: Buy
Price Target: $40
Current: $28.43
Upside: +40.70%
uniQure
Jul 29, 2026
Upgraded: Buy
Price Target: $65
Current: $44.00
Upside: +47.73%
COMPASS Pathways
Jul 7, 2026
Reiterated: Buy
Price Target: $18
Current: $15.19
Upside: +18.50%
LB Pharmaceuticals
Jul 7, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $42.47
Upside: +5.96%
Seaport Therapeutics
Jul 7, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $21.39
Upside: -
ACADIA Pharmaceuticals
May 6, 2026
Reiterated: Buy
Price Target: $33
Current: $27.29
Upside: +20.92%
Neurocrine Biosciences
Apr 6, 2026
Reiterated: Buy
Price Target: $160
Current: $146.23
Upside: +9.42%
Praxis Precision Medicines
Apr 6, 2026
Reiterated: Buy
Price Target: $500
Current: $298.95
Upside: +67.25%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $43.39
Upside: +3.71%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $230
Current: $207.78
Upside: +10.69%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $20 → $25
Current: $38.81
Upside: -35.58%
Feb 23, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $19.72
Upside: -
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $55 → $60
Current: $39.75
Upside: +50.94%
Dec 31, 2025
Initiated Coverage: Buy
Price Target: $18
Current: $8.58
Upside: +109.79%
Oct 20, 2025
Reiterated: Buy
Price Target: $15
Current: $30.27
Upside: -50.45%
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $40
Current: $0.48
Upside: +8,233.33%
May 21, 2025
Reiterated: Buy
Price Target: $80
Current: $60.98
Upside: n/a